financing

News

Ambrosia's sweet $100m round, and other biofinancings

Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.

News

Blackstone closes record $6.3bn life sciences fund

Blackstone has closed its latest fund – the $6.3bn BXLS VI – saying it is the largest ever private fund for the life sciences sector.

News

Obesity-focused biotech Kailera joins IPO queue in US

Kailera Therapeutics has filed for an IPO, hoping to whet investor appetites with its pipeline of drug candidates for weight loss.

News

Earendil raises $787m as lead TL1A antibody starts phase 2

Earendil has raised an impressive $787m in financing for its AI-powered drug platform, attracting yet more buy-in from Sanofi.

News

Kidney biotech R1's $78m debut, and other biofinancings

Biofinancing values have tailed off a bit after a strong start to 2026, but March has seen $50m+ rounds for R1, Crossbow, Excalipoint, and Prolium.

News

Alto raises $120m for resistant depression programme

Alto Neuroscience has raised $120m that will fund pivotal trials of its recently acquired candidate for treatment-resistant depression.

Ambrosia's sweet $100m round, and other biofinancings

Blackstone closes record $6.3bn life sciences fund

Obesity-focused biotech Kailera joins IPO queue in US

Earendil raises $787m as lead TL1A antibody starts phase 2

Kidney biotech R1's $78m debut, and other biofinancings

Alto raises $120m for resistant depression programme

Remepy's hybrid Parkinson's therapy poised for phase 3

Discover a new era of healthcare panel engagement: Grounded ...

financing

Editor's Picks